Access on-demand webinar >
One overarching theme throughout all of the conferences we’ve attended this year has been inopportune weather. From the heavy snowfall in Atlanta, Ga., to a snowstorm in Salt Lake City, Utah, to the threat of a major Nor’easter just this past month in Boston, we seemed to bring snow wherever we went. So, when presented with the opportunity to participate in the Cell & Gene Therapy Manufacturing Digital Week, a virtual 4-day webcast series led by industry experts, we jumped on the opportunity to avoid another interaction with a blizzard.
During the event, Jamie Margolis, PhD, director of product development operations, Be The Match BioTherapies®, presented a webinar titled: “Techniques for Navigating the Cell Therapy Supply Chain – When Exceptions are the Norm.”
Jamie shares strategies for mitigating risk throughout the cell therapy supply chain. She highlights the importance of having dedicated case managers supported by a strong software platform to ensure that therapies move from collection through infusion more efficiently and reliably. Interested in hearing Jamie’s full presentation? Check out the on-demand webinar.
Learn more about how Be The Match BioTherapies can partner with you to successfully deliver your cellular starting material or manufactured therapy from collection through infusion.
Explore cell therapy supply chain solutions >
Author: NMDP BioTherapies
NMDP BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of NMDP, and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization designs solutions that advance the development of cell and gene therapies across the globe.
NMDP BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the NMDP Registry, the world’s most diverse registry of more than 22 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection, and transplant centers worldwide, the organization develops, onboards, trains, and manages expansive collection networks to advance cell therapies. NMDP BioTherapies uses a proven infrastructure consisting of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to transport and deliver regulatory-compliant life-saving therapies across the globe successfully. Through the CIBMTR, NMDP BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.
